Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Curium Pharma

Tracked across 2 events · 12 articles · First seen Jun 11, 2026 · Last active Sep 21, 2026

Sentiment
38
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Tech
Impact: Curium Pharma, a global radiopharmaceutical company, is a key partner in the clinical development of 64Cu-PSMA-I&T and 177Lu-PSMA-I&T, leading global development and supporting technology transfer to Japan. The completion of patient dosing in the Phase 2 trial in Japan is a significant milestone for its mission to expand access to radiopharmaceuticals in Asia.
Jun 11, 2026 · 6 articles
4 5
Business
Telix Pharmaceuticals agreed to acquire privately held ITM Isotope Technologies Munich in a deal valued at up to $2.35 billion, comprising $1.65 billion upfront plus up to $700 million in contingent milestone payments. The upfront…
Impact: Recently won FDA approval for Bexlutry and is closing its $8 billion purchase of Lantheus Holdings, making it a consolidating rival to the enlarged Telix.
Sep 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Curium Pharma live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.